Cargando…
The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches
Of the many genetic alterations that occur in cancer, relatively few have proven to be suitable for the development of targeted therapies. Mutations in isocitrate dehydrogenase (IDH) 1 and -2 increase the capacity of cancer cells to produce a normally scarce metabolite, D-2-hydroxyglutarate (2-HG),...
Autores principales: | Gruber, Emily, Kats, Lev M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586776/ https://www.ncbi.nlm.nih.gov/pubmed/37526143 http://dx.doi.org/10.1042/BST20230017 |
Ejemplares similares
-
Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia
por: Mingay, M, et al.
Publicado: (2018) -
Concurrent inhibition of IDH and methyltransferase maximizes therapeutic efficacy in IDH mutant acute myeloid leukemia
por: Zeng, Zhihong, et al.
Publicado: (2021) -
Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia
por: Bassal, Mahmoud A., et al.
Publicado: (2022) -
Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
por: Gupta, Charu, et al.
Publicado: (2020) -
Cup‐like blasts in acute myeloid leukaemia with NPM1 and IDH2 mutations
por: Ohya, Eiko, et al.
Publicado: (2021)